79205-04-2

Usage

Uses

Used in Pharmaceutical Development:
2-Methyl-5-Methoxyquinoline is used as a pharmaceutical candidate for its potential biological activity and medicinal properties. Its unique structure and properties make it a valuable compound in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
As a building block in organic synthesis, 2-Methyl-5-Methoxyquinoline is utilized for the creation of various organic compounds. Its versatility in chemical reactions allows for the synthesis of a wide range of molecules with diverse applications.
Used in Antioxidant Research:
2-Methyl-5-Methoxyquinoline is used as a subject of study in antioxidant research. Its potential as an antioxidant and related effects make it an interesting compound for further investigation, with possible applications in health and wellness products, as well as in the prevention of oxidative damage in various industries.
Used in Industrial Applications:
2-Methyl-5-Methoxyquinoline's yellowish-brown color and unique properties make it suitable for use in various industrial applications, such as dyes, pigments, and other specialty chemicals. Its versatility and potential for customization make it a valuable asset in the development of new products and technologies.

Upstream product

• 54408-52-5 5-bromo-2-methylquinoline 
• 123-73-9 trans-Crotonaldehyde 
• 536-90-3 m-Anisidine 
• 123-73-9 crotonaldehyde 
• 54408-50-3 2-methyl-5-aminoquinoline 
• 23877-94-3 2-methyl-5-nitroquinoline 
• 57155-51-8 2-Methyl-quinoline-5-diazonium; bromide 
• 64-17-5 ethanol 
• 90-04-0 2-methoxy-phenylamine 
• 2401-24-3 2-chloro-5-methoxyaniline 

Downstream Products

• 852402-70-1 5-methoxyquinoline-2-carboxylic acid 
• 852402-73-4 (S)-5-methoxyquinoline-2-carboxylic acid (1-phenylethyl)amide 
• 852402-83-6 (2S,3'S)-5-methoxy-1,2,3,4-tetrahydroquinoline-2-carboxylic acid (1-phenylethyl)amide 
• 852402-78-9 (2R,3'S)-5-methoxy-1,2,3,4-tetrahydroquinoline-2-carboxylic acid (1-phenylethyl)amide 
• 852402-99-4 (4aR,1'S)-7-methoxy-3-(1-phenylethyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoline 
• 852403-04-4 (4aS,1'S)-7-methoxy-3-(1-phenylethyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoline 
• 852402-89-2 (4aR,1'S)-7-methoxy-3-(1-phenylethyl)-2,3,4,4a,5,6-hexahydropyrazino[1,2-a]quinolin-1-one 
• 852402-94-9 (4aS,1'S)-7-methoxy-3-(1-phenylethyl)-2,3,4,4a,5,6-hexahydropyrazino[1,2-a]quinolin-1-one 
• 1422841-39-1 C₂₆H₂₂N₄O₂ 
• 1422841-62-0 C₂₆H₂₂N₄O₂ 

Relevant academic research and scientific papers

BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS

Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.

TREATING CANCER WITH A BROMODOMAIN AND EXTRA-TERMINAL (BET) FAMILY INHIBITOR

Methods of treating patients diagnosed with cancer with a BET inhibitor compound are provided, including intermittent dosing schedules for administering the compound as a single agent or as part of a combination therapy. For example, AML/MDS and NHL cancer patients can be treated with a BET inhibitor compound using intermittent dosing schedules provided herein.

Rapid Construction of Structurally Diverse Quinolizidines, Indolizidines, and Their Analogues via Ruthenium-Catalyzed Asymmetric Cascade Hydrogenation/Reductive Amination

A rapid construction of enantioenriched benzo-fused quinolizidines, indolizidines, and their analogues by ruthenium-catalyzed asymmetric cascade hydrogenation/reductive amination of quinolinyl- and quinoxalinyl-containing ketones has been developed. This

TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.

HCV NS5A replication complex inhibitors. Part 4.1 optimization for genotype 1a replicon inhibitory activity

A series of symmetrical E-stilbene prolinamides that originated from the library-synthesized lead 3 was studied with respect to HCV genotype 1a (G-1a) and genotype 1b (G-1b) replicon inhibition and selectivity against BVDV and cytotoxicity. SAR emerging f

Identification and development of an efficient route to SB-649915

The discovery and development of an efficient manufacturing route to the SSRI-5-HT1A receptor antagonist 6-[(1-{2-[(2-methyl-5-quinolinyl)oxy]ethyl}-4- piperidinyl)methyl]-2H-1,4-benzoxazin-3(4H)-one (SB-649915) 1 is described. The existing route to 1 involved coupling quinoline 6 with piperidine 5 and was considered lengthy as a consequence of the nine synthetic steps required to prepare 5. Two new routes to the key piperidine intermediate 5 are identified which deliver this compound in five and two steps respectively, from readily available materials using novel lithiation and Friedel-Crafts methodology respectively. The latter of these two routes was successfully demonstrated at 5 L scale to deliver 700 g of 5. Development to the methanesulfonate 34, an alternative to quinoline 6, is also described as is the final alkylation of piperidine 5 with this methanesulfonate 34 to deliver SB-649915 1.

Au-doped TiO2 nanoparticles for selective photocatalytic synthesis of quinaldines from anilines in ethanol

A convenient eco-friendly photocatalytic synthesis of quinaldines has been developed by a simple one-pot reaction of anilines in ethanol solution with Au-loaded TiO2 under UV irradiation. Upon irradiation in the presence of Au-TiO2, aniline and oxidation products derived from ethanol undergo condensation-cyclization to afford quinaldines.

Electrophilic aromatic addition reaction: Electrophilic attack at an aromatic H substituent position

(Chemical Equation Presented) We report and propose a mechanism for an unusual electrophilic aromatic addition reaction (AdEAr). During our preparation of 5,7-dibromo-8-methoxyquinaldine as a key intermediate in the synthesis of 7-bromoquinaldine-5,8-dione, direct bromination in either acidic or neutral conditions led only to the formation of 5-bromo-8-methoxyquinaldine. Under basic methanolic conditions, however, we unexpectedly obtained the 5,7-dibromo-8,8-dimethoxy-7,8-dihydroquinaldine adduct 2a. This result not only allows for the functionalization of aromatic compounds via the addition adducts, but also introduces the possibility of an alternate mechanism for electrophilic substitution reactions.